iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

NEXT STORY
Gritstone Oncology Announces Private Placement Financings Totaling $125 Million
PREV STORY
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease

CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a ...

author_avatar
NASDAQ Market News

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

author_avatar
NASDAQ Market News

Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care

author_avatar
NASDAQ Market News